TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 Ig… Read more
Market Cap & Net Worth: TRACON Pharmaceuticals Inc (TCON)
TRACON Pharmaceuticals Inc (OTCQB:TCON) has a market capitalization of $109.73K ($109.73K) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #40817 globally and #13237 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TRACON Pharmaceuticals Inc's stock price $0.03 by its total outstanding shares 3407610 (3.41 Million).
TRACON Pharmaceuticals Inc Market Cap History: 2025 to 2025
TRACON Pharmaceuticals Inc's market capitalization history from 2025 to 2025. Data shows growth from $109.73K to $109.73K (0.00% CAGR).
TRACON Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TRACON Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TCON by Market Capitalization
Companies near TRACON Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to TRACON Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
TRACON Pharmaceuticals Inc Historical Marketcap From 2025 to 2025
Between 2025 and today, TRACON Pharmaceuticals Inc's market cap moved from $109.73K to $ 109.73K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $109.73K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of TRACON Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $109.73K USD |
| MoneyControl | $109.73K USD |
| MarketWatch | $109.73K USD |
| marketcap.company | $109.73K USD |
| Reuters | $109.73K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.